An observational study in Rectal Cancer Patients, sponsored by The Institute of Molecular and Translational Medicine, Czech Republic. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by The Institute of Molecular and Translational Medicine, Czech Republic · Observational
The prospective study will focus on patients undergoing multimodal treatment for rectal cancer. The main objective of the study will be to monitor changes in circulating tumor cells (CTCs) in the peripheral blood of patients during multimodal treatment. For each patient enrolled in the study, peripheral blood samples will be collected at specified time intervals to determine the presence and quantity of CTCs.
The CTCs levels will be compared among rectal cancer patients with neoadjuvant chemoradiotherapy and without neoadjuvant chemotherapy.
227 studies on the registry are indexed under Neoplastic Cells, Circulating; 54 are open to participants now.
This study's planned enrollment of 150 is above the median of 120 across 121 observational studies indexed under Neoplastic Cells, Circulating.
Browse Neoplastic Cells, Circulating studies →The Institute of Molecular and Translational Medicine, Czech Republic is the lead sponsor of 18 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Rectal cancer patients
Inclusion Criteria: rectal cancer -
Exclusion Criteria: no other cancer
-
Levels of circulating tumor cells in peripheral blood
The levels of circulating tumor cells will be measured in rectal cancer patients
Time frame: The levels of circulating tumor cells will be measured in 5 time points: before neoadjuvant chemoradiotherapy, in 3. week of chemoradioterapy, before surgery, one week after surgery and one month after surgery.
Plan to share: Yes — Patients code; sex; age; diagnosis; clinical, laboratory and experimental findings
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Started May 2023 (actual). Primary completion is estimated for Dec 2026, 43 months after the start.
Of 59 observational studies under Neoplastic Cells, Circulating, half reached primary completion within 93 months of starting (the median), counting those still running; a quarter within 38. This study's planned 43 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neoplastic Cells, Circulating →
The Institute of Molecular and Translational Medicine, Czech Republic